EyePoint (EYPT) Cash from Financing Activities (2011 - 2026)
EyePoint (EYPT) posted Cash from Financing Activities of -$2.6 million for Q1 2026, down 101.57% sequentially from $167.0 million in Q4 2025, and down 174.87% YoY from $3.5 million in Q1 2025.
EyePoint (EYPT) Cash from Financing Activities (2011 - 2026) Analysis & Trends
EyePoint has reported Cash from Financing Activities for 16 years, with the latest figure at -$2.6 million in Q1 2026.
- Quarterly Cash from Financing Activities fell 174.87% year-over-year to -$2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172.0 million (up 5.54% YoY) and the FY2025 annual result came in at $173.6 million, up 5.87% from the prior year.
- Cash from Financing Activities fell to -$2.6 million in Q1 2026 per EYPT's latest filing, from $167.0 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $218.5 million in Q4 2023 and troughed at -$36.7 million in Q2 2023.
- A 5-year average of $30.7 million and a median of $115000.0 in 2024 frame the typical range for Cash from Financing Activities.
- The widest YoY moves for Cash from Financing Activities: up 376798.28% in 2023, down 13181.88% in 2023.
- Over 5 years, Cash from Financing Activities stood at -$58000.0 in 2022, then surged by 376798.28% to $218.5 million in 2023, then tumbled by 30.57% to $151.7 million in 2024, then increased by 10.07% to $167.0 million in 2025, then plunged by 101.57% to -$2.6 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$2.6 million, $167.0 million, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | EyePoint | 1.25 Bn | 1.07 Bn | 507,000.00 | 19.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.99 Mn |
| Jun 30, 2026 | 19.99 Mn |
| Mar 31, 2026 | -2.61 Mn |
| Mar 31, 2026 | -2.61 Mn |
| Dec 31, 2025 | 166.96 Mn |
| Dec 31, 2025 | 166.96 Mn |
| Sep 30, 2025 | 7.40 Mn |
| Sep 30, 2025 | 7.40 Mn |
| Jun 30, 2025 | 238,000.00 |
| Jun 30, 2025 | 238,000.00 |
| Mar 31, 2025 | -951,000.00 |
| Mar 31, 2025 | -951,000.00 |
| Dec 31, 2024 | 151.69 Mn |
| Dec 31, 2024 | 151.69 Mn |
| Sep 30, 2024 | 11.89 Mn |
| Sep 30, 2024 | 11.89 Mn |
| Jun 30, 2024 | 329,000.00 |
| Jun 30, 2024 | 329,000.00 |
| Mar 31, 2024 | 115,000.00 |
| Mar 31, 2024 | 115,000.00 |